<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01402843</url>
  </required_header>
  <id_info>
    <org_study_id>CWP-PTV-301</org_study_id>
    <nct_id>NCT01402843</nct_id>
  </id_info>
  <brief_title>Efficacy, Safety of Coadministered Pitavastatin and Valsartan in Patients With Hypertension and Dyslipidemia</brief_title>
  <acronym>COCTAIL</acronym>
  <official_title>A Randomized, Double Blind, Double Dummy, Placebo Controlled Phase III Trial to Evaluate the Efficacy, Safety of Coadministered Pitavastatin and Valsartan in Patients With Hypertension and Dyslipidemia(COCTAIL Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>JW Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>JW Pharmaceutical</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pitavastatin, a representative statin-series anti-dyslipidemic drug, and Valsartan, a&#xD;
      representative ARB-series anti-hypertensive drug, have been authorized for use also in South&#xD;
      Korea. They have been tested in many countries and proved to be effective and safe. The&#xD;
      concurrence of dyslipidemia and hypertension has a higher rate, hence statin-series drugs and&#xD;
      antihypertensive drugs are simultaneously administered to such patients. The combined&#xD;
      administration of statin-series drugs and CCB-series drugs have.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This clinical trial was conducted to evaluate the safety and effectiveness of the combined&#xD;
      administration of Pitavastatin and Valsartan to ethnic Koreans with dyslipidemia concurrent&#xD;
      with hypertension, as well as to research the influence on the pharmacodynamic interaction&#xD;
      between the two drugs.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2011</start_date>
  <completion_date type="Actual">January 2013</completion_date>
  <primary_completion_date type="Actual">June 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The experimental group should be compared with control group in the change of DBP and LDL-C on the basis of the baseline.</measure>
    <time_frame>8 week</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Systolic Blood Pressure at 6 months.</measure>
    <time_frame>8 week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The changes and rate of lipid variables (TG, TC, HDL cholesterol and apolipoprotein B)</measure>
    <time_frame>8 week</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Hypertension</condition>
  <condition>Dyslipidemia</condition>
  <arm_group>
    <arm_group_label>pitavastatin + valsartan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>pitavastatin + placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>valsartan + placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pitavastatin, valsartan, placebo</intervention_name>
    <description>pitavastatin 4mg/day 8 week valsartan 320mg/day 8 week</description>
    <arm_group_label>pitavastatin + placebo</arm_group_label>
    <arm_group_label>pitavastatin + valsartan</arm_group_label>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_label>valsartan + placebo</arm_group_label>
    <other_name>Livalo, Diovan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients aged 20 and older&#xD;
&#xD;
          2. Patients with Dyslipidemia&#xD;
&#xD;
          3. Patients with hypertension&#xD;
&#xD;
          4. Patients who voluntarily signed the consent form.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Blood Pressure&#xD;
&#xD;
               -  In case there is a sitting systolic blood pressure difference of 20mmHg and over&#xD;
                  or sitting diastolic blood pressure is 10mmHg and over in selected arm.&#xD;
&#xD;
               -  Patients with symptomatic orthostatic hypotension.&#xD;
&#xD;
               -  Patients having the history of Secondary hypertension or suspected to be&#xD;
                  Secondary hypertension, e.g., aortic coarctation, hyperaldosteronism, renal&#xD;
                  artery stenosis, Cushing's disease, pheochromocytoma, polycystic renal disease,&#xD;
                  etc.&#xD;
&#xD;
          2. Patients with severe heart diseases (NYHA class-III and IV), with ischemic heart&#xD;
             diseases (angina pectoris and myocardial infarction) and with peripheral vascular&#xD;
             diseases, and patients who underwent percutaneous transluminal coronary angioplasty&#xD;
             (PTCA) or treatments for coronary artery bypass graft within 6 months.&#xD;
&#xD;
          3. Patients with clinically significant ventricular tachycardia or atrial fibrillation or&#xD;
             atrial flutter, and patients with arrhythmia judged to be clinically significant by&#xD;
             investigators.&#xD;
&#xD;
          4. Patients with hypertrophic obstructive cardiomyopathy, severe obstructive CAD, aortic&#xD;
             stenosis and hemodynamically significant aortostenosis or mitral stenosis.&#xD;
&#xD;
          5. Patients with severe cerebrovascular diseases.&#xD;
&#xD;
          6. Patients with severe or malignant retinosis.&#xD;
&#xD;
          7. Patients with consumption diseases or autoimmune diseases or connective tissue&#xD;
             diseases&#xD;
&#xD;
          8. Patients with endocrine or metabolic diseases that are known to affect serum lipid or&#xD;
             lipoprotein.&#xD;
&#xD;
               -  Patients with uncontrollable diabetes&#xD;
&#xD;
               -  Patients with uncontrollable thyroid dysfunction&#xD;
&#xD;
          9. Patients who underwent treatments that may affect lipid before the clinical trial.&#xD;
&#xD;
         10. Patients having the history of myopathy or rhabdomyolysis.&#xD;
&#xD;
         11. Patients with severe renal disorders or hepatic disorders.&#xD;
&#xD;
         12. Patients with gastrointestinal diseases that may affect drug absorption, distribution,&#xD;
             metabolism and excretion or who underwent such operations, or patients with present&#xD;
             active gastritis or gastrointestinal hemorrhage or proctorrhagia or active and&#xD;
             inflammatory bowel syndrome that has occurred within 12 months.&#xD;
&#xD;
         13. All of patients with chronic inflammatory diseases whereto anti-inflammatory&#xD;
             treatments need to be applied.&#xD;
&#xD;
         14. Patients having the history of drug or alcohol abuse.&#xD;
&#xD;
         15. Pregnant women and/or women in the lactation period or the child-bearing period.&#xD;
&#xD;
         16. Patients who are hypersensitive to Pitavastatin and Valsartan.&#xD;
&#xD;
         17. Patients who have taken other investigational drugs within 3 months before undergoing&#xD;
             the screening test for this clinical trial.&#xD;
&#xD;
         18. Patients judged to be unsuitable for this clinical trial by investigators.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gyu Rok Han, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dept. of Cardiology, Hallym University Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Chungbuk National University Hospital</name>
      <address>
        <city>Chung Ju</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Konyang University Hospital</name>
      <address>
        <city>Daejeon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gangnam Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hallym University Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Korea University Guro Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ajou University Medical Center</name>
      <address>
        <city>Suwon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <study_first_submitted>July 14, 2011</study_first_submitted>
  <study_first_submitted_qc>July 25, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 26, 2011</study_first_posted>
  <last_update_submitted>May 12, 2014</last_update_submitted>
  <last_update_submitted_qc>May 12, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 14, 2014</last_update_posted>
  <responsible_party>
    <name_title>Gyu Rok Han / MD</name_title>
    <organization>Hallym University Medical Center</organization>
  </responsible_party>
  <keyword>phase III combination study</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Dyslipidemias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Valsartan</mesh_term>
    <mesh_term>Pitavastatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

